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mTOR/p70S6K in Diffuse Idiopathic Pulmonary
Neuroendocrine Cell Hyperplasia
To the Editor:
We read with interest the review article by Nassar and coworkers
(1) on diffuse idiopathic pulmonary neuroendocrine cell hyperpla-
sia (DIPNECH). As correctly reported by the authors, this
uncommon, possibly underrated, and often indolent disease may
lead to severe respiratory obstructive symptoms and finally to
death. In symptomatic patients, therapeutic options are limited
to steroids, surgical lung resections, and lung transplantation.
Whatever the pathogenesis underlying the occurrence of
DIPNECH, respiratory functions were deteriorated by a diffuse
constrictive bronchiolitis secondary to fibrogenic peptides pro-
duced by the proliferating neuroendocrine cells (2, 3).
Pulmonary and extrapulmonary neuroendocrine cell prolif-
erations are characterized by a consistent expression of somato-
statin receptors (SSR) (mainly types 2 and 5) and of mammalian
target of rapamycin (mTOR) (4). These findings represent
a solid scientific rationale in explaining the good clinical results
recently reported with selective somatostatin analogs and
mTOR inhibitors in neuroendocrine tumors (5). Little is known
about the expression of SSR and mTOR in DIPNECH. Gorsh-
tein and colleagues (6) recently highlighted the important role
of SSR in DIPNECH showing a high uptake in all 11 cases
tested by 111In-pentetreotide scintigraphy (Octreoscan) or
gallium-68 (68Ga) 1,4,7,10-tetra-azacyclododecane-N,N9,N99,
N999-tetraacetic acid-Tyr3-octreotide/Na3-octreotide 68Ga-
labeled 1,4,7,10-tetraazacyclododecane-N,N9,N,N9-tetraacetic
acid positron emission/computed tomography imaging. In addi-
tion, six patients with progressive respiratory symptoms treated
with somatostatin analogs experienced disease stabilization with
consistent improvement of respiratory functions in four cases.
To our knowledge, there are no data aboutmTOR-relatedmol-
ecule expression in DIPNECH. By immunohistochemistry, we
tested phosphorylated-mTOR (p-mTOR) and its major target,
namely the ribosomal p70S6-kinase (p70S6K), in four cases
of DIPNECH collected from our archival files. All these cases
were characterized by the presence of a typical carcinoid and
foci of neuroendocrine hyperplasia as well as tumorlets. On im-
munohistochemistry, a robust and diffuse expression of p-mTOR
and p70S6K was observed in all neuroendocrine lesions. Thus,
the activation of mTOR pathway in DIPNECH seems to be en-
tirely similar to what has been observed in sporadic carcinoid
tumors (4).
Although preliminary, these results seem to support a scien-
tific rationale in adopting mTOR inhibitors in DIPNECH and
then to widen the spectrum of therapeutic tools in this intriguing
disease.
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From the Authors:
We appreciate the interest and comments by Dr. Rossi and col-
leagues regarding our article (1). As with many diseases, aware-
ness and recognition encourage progress in treatment. Recent
publications and discussions within the past year have brought
to the forefront treatment strategies in extrapulmonary neuroen-
docrine tumors that may be relevant to pulmonary proliferations
expressing somatostatin receptors (SSR) (2, 3). Although little is
known about the expression of SSR and mammalian target of
rapamycin (mTOR) in DIPNECH, the information highlighted
by Gorshtein, Righi, and colleagues (4, 5) complements our clin-
ical paper and illustrates the need to better understand the im-
portant role of somatostatin analogs (SSA) and their potential for
treatment in DIPNECH. Neuroendocrine cell proliferation with
somatostatin receptor expression is the fundamental pathologic
response to probable injury, so it makes teleological sense that
SSA may be beneficial in the therapeutic paradigm.
The discussion of immunohistochemistry evidence, including
the activation of the mTOR pathway in DIPNECH, is an
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excellent example of the progress that can be made with recog-
nition and international collaboration on this disease. These
leads may result in successful treatment strategies utilizing
mTOR inhibitors in DIPNECH.
Another point of importance is the role of octreotide analog
radio-labeled nuclear scintigraphy with positron emission/
computed tomography imaging (6) in perhaps guiding treatment
where the density of SSR in DIPNECH patients may predict
therapeutic success with SSA.
As with most uncommon and often unrecognized diseases,
collaboration may be the only way to obtain the volume of
patients required to properly strategize and assess treatments.
True progress and treatment algorithms would be best served
with the establishment of an international registry for patients,
a tissue repository, and the synergy of knowledge and experience
between institutions.
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Camphor, an Old Cough Remedy with
a New Mechanism
To the Editor:
In an interesting correspondence, Patberg and colleagues (1)
have commented on a recent proposal by Birring (2) on unex-
plained chronic cough (UCC). The hypothesis regards the role
of the transient receptor potential vanilloid (TRPV)1 channel as
a common final pathway underlying the heightened cough sen-
sitivity of individuals with UCC. The presence of TRPV1 in
vagal afferents, the successful use of the selective TRPV1 stim-
ulant, capsaicin, as a protussive agent in experimental animals
and humans, and the lower threshold to capsaicin-induced
cough in patients with UCC have suggested (and Dr. Birring
has reconsidered this hypothesis) a central role for TRPV1
hyperexpression and hyperfunction in chronic cough. Patberg
and coworkers (1) further supported this hypothesis with the
observation that an old cough remedy, camphorated oil, con-
tains camphor, which initially stimulates but then strongly
desensitizes TRPV1. Clinical evidence for the antitussive action
of camphor has been also reported in their comment (1). We
agree with the proposed hypothesis and with the implied ther-
apeutic perspectives for TRPV1 desensitizers/antagonists. How-
ever, camphor can no longer be regarded as a selective agent for
TRPV1. Rather, camphor has been identified as a TRPA1 (“A”
stands for ankyrin) channel antagonist. TRPA1 is coexpressed
with TRPV1 in nociceptive neurons, including vagal afferents;
various TRPA1 agonists, including cinnamaldehyde and acro-
lein, cause cough by TRPA1 stimulation in guinea pigs (3) and
humans (4); and camphor reduces TRPA1-mediated cough (3).
Also, menthol (mentioned in the comment by Patberg and col-
leagues) (1), an agonist of the cold receptor TRPM8 (and via
this mechanism responsible for the fresh sensation associated
with mint), and traditionally used as a cough remedy, has been
found to inhibit TRPA1 (5). Thus, while we recognize the pos-
sible role of TRPV1 in the mechanism of UCC, we recommend
that the emerging role of TRPA1 not be disregarded. This is of
particular relevance when considering the peculiar chemical
features of TRPA1, which are responsible for the unique ability
of this channel to sense a series of irritant and reactive endog-
enous (associated with inflammation and tissue injury) and ex-
ogenous (associated with environmental pollution) molecules,
derived from oxidative and nitrative stress (6). Following the
advice of the children’s song “John Brown’s baby had a cough,”
the future challenge in drug discovery for the treatment of
chronic cough would be better suited by a compound that more
efficiently and safely combines the blocking property of cam-
phor at both TRPV1 and TRPA1.
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